ARTICLE | Company News

Regado Biosciences, Tobira deal

January 19, 2015 8:00 AM UTC

Tobira will acquire Regado through a reverse merger in a deal slated to close next quarter. The combined company, which will be named Tobira Therapeutics Inc., plans to develop treatments for liver and inflammatory diseases, including non-alcoholic steatohepatitis (NASH). Tobira CEO Laurent Fischer will lead the combined entity. Regado’s shareholders will own about 32% of the merged company, while Tobira’s shareholders will own the balance. ...